Who are Fosamax's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Boniva, Zometa, Aredia, alendronate, OST, Ibandronate (SB743830HD).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/alendronic-acid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Fosamax — Competitive Intelligence Brief

Fosamax (ALENDRONIC ACID) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin D [EPC]. Area: Bone.

marketed Vitamin D [EPC] Farnesyl pyrophosphate synthase Bone Small molecule Live · refreshed every 30 min

Target snapshot

Fosamax (ALENDRONIC ACID) — Merck And Co Inc. Fosamax works by inhibiting bone resorption, allowing bone density to increase.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fosamax TARGET	ALENDRONIC ACID	Merck And Co Inc	marketed	Vitamin D [EPC]	Farnesyl pyrophosphate synthase	1995-01-01
Boniva	IBANDRONIC ACID	Hoffmann La Roche	marketed	Bisphosphonate	Farnesyl pyrophosphate synthase	2003-01-01
Zometa	ZOLEDRONIC ACID	Novartis	marketed	zoledronic acid	Farnesyl pyrophosphate synthase	2001-01-01
Aredia	PAMIDRONIC ACID		marketed	Bisphosphonate	Farnesyl pyrophosphate synthase	1991-01-01
alendronate	alendronate	Massachusetts General Hospital	marketed		Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, EC 2.5.1.1, EC 2.5.1.10
OST	OST	Pharmbio Korea Co., Ltd.	marketed	Bisphosphonate	Farnesyl pyrophosphate synthase
Ibandronate (SB743830HD)	Ibandronate (SB743830HD)	GlaxoSmithKline	marketed	Bisphosphonate	Farnesyl pyrophosphate synthase; hydroxyapatite in bone

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2031-12-05 — Fosamax · 9592195 · US

Sponsor landscape (Vitamin D [EPC] class)

· 2 drugs in this class
Abramson Cancer Center at Penn Medicine · 1 drug in this class
Eli Lilly · 1 drug in this class
Heather Wakelee · 1 drug in this class
Merck And Co Inc · 1 drug in this class
Mohammed Milhem, MBBS · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fosamax — Competitive Intelligence Brief. https://druglandscape.com/ci/alendronic-acid. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab